Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

MRUS Merus NV

56,99

0,21 (0,37%)

27 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Merus NV (NASDAQ:MRUS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Merus NV Charts.

Merus NV (NASDAQ:MRUS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Merus NV Charts.

News Merus NV

Form 144 - Report of proposed sale of securities
Montag 17 Juni 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 12 Juni 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 6 Juni 2024 (3 Wochen vor) • Edgar (US Regulatory)

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
Montag 3 Juni 2024 (3 Wochen vor) • GlobeNewswire Inc.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
Sonntag 2 Juni 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]
Donnerstag 30 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Merus Announces Pricing of Upsized Public Offering of Common Shares
Donnerstag 30 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
Mittwoch 29 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]
Dienstag 28 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 28 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Merus N.V. Announces Proposed Public Offering of Common Shares
Dienstag 28 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
Dienstag 28 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Weitere Merus NV News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen